This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

United Therapeutics' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Martine Rothblatt

Thanks for those questions. I would say both of those fall more in the sales and marketing category, so I'm going to ask Dr. Jeffs, our President, to kindly address those.

Roger A. Jeffs

That you, Martine. The way, as we said before, that there is quarter-to-quarter fluctuation in ordering patterns from our main customers, which are the specialty pharmacies. And I think this quarter is reflective of normal variations within quarters.

When we look going forward into 2012, we see the majority of the growth coming from Tyvaso and Adcirca in terms of incremental revenue addition. However, the core base of Remodulin revenue, we expect to remain stable and grow slightly as well. So we think there should be growth within the full suite of products that we sell and we remain confident on guidance for 2012 at the 875 range as previously stated.

Martine Rothblatt

Thanks, Roger. Thank you, questioner from Collin Stewart. Operator, could you please open the line to the next question.

Operator

Absolutely. Our next question comes from the line of Liana Moussatos from Wedbush Securities. Your line is now open, please go ahead.

Liana Moussatos - Wedbush Securities Inc.

Thank you for taking my question. Can you give us the geographic breakdown of Remodulin sales, Europe and U.S.?

Martine Rothblatt

Thanks Liana, nice to hear your voice this morning. I think it probably would be more in John Ferrari's category to give the breakdown of revenues ex-U.S. and U.S. So John could you please help with that question?

John M. Ferrari

I'd be happy to. We haven't seen any significant fluctuation between U.S. and non-U.S. sales for Remodulin that we reported over the years, so somewhere between 13 and 15% of our Remodulin revenues come the rest of the world or outside the U.S.

Martine Rothblatt

Thanks, John. Thanks, Liana. Operator, can you please take the next question?

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs